NCT05429008View on ClinicalTrials.gov

A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

April 7, 2025

Study Completion Date

April 7, 2025

Conditions
Advanced Tumors
Interventions
DRUG

HMPL-A83 injection

Day 1,8,15,22 dose; 28 day treatment cycles.

Trial Locations (4)

Unknown

Harbin Medical University Cancer Hospital, Harbin

The First Affiliated Hospital of Nanchang University, Nanchang

Shandong Cancer Hospital, Shandong

Shanghai Orient Hospital, Shanghai

Sponsors

Lead Sponsor

Hutchmed
All Listed Sponsors
lead

Hutchmed

INDUSTRY